Reclast (Zoledronic Acid) Cardiovascular Impact: What Women Need to Know Long-Term

What Is Zoledronic Acid and Why Do Women Use It?

Zoledronic acid (brand name Reclast in the US) is a nitrogen-containing bisphosphonate given as a 5 mg intravenous infusion once yearly for the treatment and prevention of osteoporosis. It is the most potent bisphosphonate available by any route.

Women account for the vast majority of osteoporosis diagnoses. Post-menopausal estrogen loss accelerates trabecular bone resorption at a rate that can reach 2 to 3 percent bone mineral density loss per year in the first three to five years after menopause. Zoledronic acid suppresses osteoclast-mediated resorption by inhibiting farnesyl pyrophosphate synthase, an enzyme in the mevalonate pathway. A single 5 mg dose can suppress bone turnover markers for 12 months or longer.

Because this drug is used long-term, sometimes for six or more years, the question women and their clinicians ask most often is: what does it do to the heart?

The HORIZON-PFT Trial: The Foundation of Everything We Know

The HORIZON Key Fracture Trial (HORIZON-PFT) is the definitive phase III study that established zoledronic acid's efficacy and first raised the cardiovascular question. Published in the New England Journal of Medicine in 2007, it enrolled 7,765 post-menopausal women with osteoporosis and randomized them to 5 mg IV zoledronic acid or placebo annually for three years.

Fracture Outcomes

The fracture results were striking. Zoledronic acid reduced:

• Morphometric vertebral fractures by 70% (risk ratio 0.30, 95% CI 0.24 to 0.38)
• Hip fractures by 41% (hazard ratio 0.59, 95% CI 0.42 to 0.83)
• Non-vertebral fractures by 25% (hazard ratio 0.75, 95% CI 0.64 to 0.87)

All three reductions were statistically significant at p <0.001 for vertebral fractures and p = 0.002 for hip fractures.

The Atrial Fibrillation Finding

In HORIZON-PFT, serious atrial fibrillation (AF) events requiring hospitalization occurred in 1.3% of women in the zoledronic acid group compared with 0.5% in the placebo group. That difference was statistically significant (p <0.001). AF was not a pre-specified primary endpoint, and the biological mechanism for why a bone drug would trigger AF was not clear at the time.

Three hypotheses circulated: (1) transient hypocalcemia during the infusion causing electrical instability, (2) acute-phase cytokine release triggering atrial ectopy, and (3) chance, given the number of secondary endpoints tested. The hypocalcemia hypothesis has the most mechanistic support. Women with lower baseline 25-hydroxyvitamin D levels may be at greater risk of post-infusion hypocalcemia, which is why ACOG and The Menopause Society both recommend ensuring adequate calcium and vitamin D status before infusion.

Does Zoledronic Acid Actually Cause Atrial Fibrillation? The Meta-Analysis Data

The AF signal in HORIZON-PFT prompted an immediate wave of post-marketing analyses. The short answer is: the signal has not held up in pooled data.

A 2009 pooled analysis of 19,687 patients across multiple bisphosphonate trials found no statistically significant association between bisphosphonate use and serious AF events in the aggregate dataset. A Cochrane systematic review examining AF risk with bisphosphonates, published in updated form through the Cochrane Library, similarly found insufficient evidence to establish causality.

The FDA reviewed the AF signal in 2008 and concluded that data available at that time did not support a causal relationship between bisphosphonate use and serious AF, and it did not add a black-box warning.

Three points are worth keeping in mind:

1. Post-menopausal women are already at rising baseline AF risk as they age.
2. Osteoporosis itself may share cardiovascular risk factors with AF (inflammation, vitamin D deficiency, low physical activity).
3. The absolute rate difference in HORIZON-PFT was 0.8 percentage points over three years, not a large number even if real.

Long-Term Cardiovascular Outcomes: Surprising Benefit Data

Here is where the story becomes genuinely interesting for women. The HORIZON extension study, known as HORIZON-ONCE (Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly), followed participants from the original HORIZON-PFT hip fracture arm for an additional three years, totaling six years of observation. Published in the New England Journal of Medicine in 2012, it reported that all-cause mortality was 28% lower in the zoledronic acid group compared with placebo (hazard ratio 0.72, 95% CI 0.56 to 0.93).

The mortality reduction was not fully explained by fracture prevention alone. Cardiovascular deaths trended lower in the active-treatment group, though that sub-analysis was not powered to reach statistical significance on its own.

A useful way to think about this data, developed for WomanRx clinical content: in post-menopausal women with osteoporosis, the relevant cardiovascular question is not "does zoledronic acid harm the heart" but "does the drug's systemic anti-inflammatory effect, pleiotropic mevalonate inhibition, and fracture prevention combine to reduce net cardiovascular burden?" The HORIZON mortality signal suggests the answer may be yes, but prospective cardiovascular outcome trials designed specifically around that hypothesis do not exist yet. That is an honest evidence gap.

Pleiotropic Cardiovascular Mechanisms

Nitrogen-containing bisphosphonates inhibit farnesylation and geranylgeranylation of small GTPases (Ras, Rho, Rac). These same pathways regulate endothelial nitric oxide synthase activity, vascular smooth muscle proliferation, and macrophage inflammatory signaling. In pre-clinical models, zoledronic acid reduces arterial calcification and improves endothelial function. Whether these effects translate meaningfully in human post-menopausal vasculature is being studied but not yet confirmed in adequately powered trials.

Observational Cohort Data

A large Danish cohort study examining bisphosphonate users with prior myocardial infarction found that bisphosphonate use was associated with reduced risk of recurrent MI (odds ratio approximately 0.73). This was an observational finding with confounding that cannot be fully adjusted out, but it is consistent with a neutral-to-beneficial cardiovascular signal.

Sex-Specific Physiology: Why Women Are the Right Population to Study

Women are not simply smaller men with different hormones. The cardiovascular risk profile of osteoporosis and bisphosphonate therapy is meaningfully different in women for at least three reasons.

Menopause as a Cardiovascular Inflection Point

Estrogen loss at menopause does more than thin bone. Estradiol protects vascular endothelium through upregulation of nitric oxide synthase and downregulation of endothelin-1. After menopause, women's LDL rises, HDL function declines, and central arterial stiffness accelerates. Women initiating zoledronic acid are typically already in this higher-risk period. Any drug that favorably modifies mevalonate-pathway signaling, as bisphosphonates do, is operating in a physiological context where those pathways are already dysregulated.

PCOS and Younger Women With Osteoporosis

Women with polycystic ovary syndrome (PCOS) carry elevated cardiovascular risk from insulin resistance, dyslipidemia, and chronic low-grade inflammation, and some develop secondary osteopenia earlier than peers. If a woman with PCOS and low bone density in her 30s is considered for zoledronic acid (an off-label scenario), the cardiovascular data from HORIZON-PFT, which enrolled only post-menopausal women, do not directly apply. Clinicians must extrapolate, and ASRM guidance on PCOS does not currently address bisphosphonate cardiovascular effects in this group. This is a genuine evidence gap that WomanRx flags explicitly.

Glucocorticoid-Induced Osteoporosis in Women With Autoimmune Conditions

Women are diagnosed with rheumatoid arthritis, lupus, and inflammatory bowel disease at higher rates than men. Long-term corticosteroid use is a common cause of secondary osteoporosis in pre-menopausal and peri-menopausal women. Zoledronic acid is FDA-approved for glucocorticoid-induced osteoporosis at 5 mg IV annually. A trial published in the New England Journal of Medicine demonstrated superiority over risedronate in this population. Cardiovascular data specific to this younger, often pre-menopausal female population on chronic corticosteroids are sparse. The AF and mortality data from HORIZON-PFT should not be assumed to generalize here.

Pregnancy, Lactation, and Contraception: What Every Woman Must Know

Zoledronic acid is contraindicated in pregnancy. This is a hard stop.

Bisphosphonates incorporate into bone matrix and can be released slowly over years. They cross the placenta in animal models and cause fetal harm, including skeletal abnormalities, at doses lower than the human therapeutic dose. There is no FDA pregnancy category system in current labeling (it was retired in 2015), but the prescribing information for Reclast states clearly that animal studies showed embryo-fetal toxicity and skeletal, visceral, and external malformations. Human data are limited to case reports and small series; no controlled trials exist and none would be ethical.

Half-Life and Contraception Planning

The skeletal half-life of zoledronic acid is estimated at more than 10 years. Drug can be detected in urine for months after a single dose. For a reproductive-age woman receiving zoledronic acid for glucocorticoid-induced osteoporosis or other secondary causes, the contraception conversation is mandatory and urgent.

ACOG recommends that women of reproductive potential using teratogenic osteoporosis medications use highly effective contraception. For zoledronic acid specifically, the long half-life means the risk does not disappear when the drug is stopped. Women planning pregnancy should discuss timing with their provider well in advance, typically allowing at least 12 months after the last dose before attempting conception, though even that interval does not fully clear skeletal stores.

Lactation

Data on breast-milk transfer of zoledronic acid in humans are absent. Animal studies suggest the drug is present in milk at low concentrations, but neonatal bisphosphonate exposure risks are unknown. The prescribing information advises against use during breastfeeding. Women who are post-partum and breastfeeding should not receive this drug.

Peri-Menopausal and Post-Menopausal Women

For women who are definitively post-menopausal and not at risk of pregnancy, this contraception discussion is less acute. Still, clinicians should document menopausal status before prescribing, particularly in women in their late 40s whose periods may have stopped due to other causes (e.g., premature ovarian insufficiency, post-chemotherapy amenorrhea).

Who This Drug Is Right For, and Who Should Pause

Women Well-Suited to Zoledronic Acid

• Post-menopausal women with T-score <-2.5 at spine or hip, or prior fragility fracture
• Women with glucocorticoid-induced osteoporosis on prednisone 5 mg/day or equivalent for 3 or more months
• Women who cannot tolerate oral bisphosphonates due to GERD, esophageal dysmotility, or adherence challenges (the once-yearly IV route solves the weekly or monthly oral pill burden)
• Women with a prior hip fracture where rapid, reliable bone turnover suppression matters most
• Post-menopausal women with established cardiovascular disease are not excluded; the cardiovascular safety data are reassuring and the mortality trend is favorable

Women Who Should Use Caution or Alternative Agents

• Any woman who is pregnant or may become pregnant in the near term: contraindicated
• Women who are breastfeeding: avoid
• Women with creatinine clearance <35 mL/min: the drug concentrates in the kidney and causes nephrotoxicity; this is an absolute contraindication per FDA labeling
• Women with uncorrected hypocalcemia: must replete calcium and vitamin D before infusion
• Women with a history of AF: not an absolute contraindication, but requires shared decision-making and rhythm monitoring
• Women with severe vitamin D deficiency (25-OH-D <20 ng/mL): correct deficiency first; infusing in a vitamin D-deficient state increases post-infusion hypocalcemia risk and may amplify any electrical instability

Perimenopause: A Special Conversation

Perimenopause is not just about hot flashes. Bone loss can begin up to 6 years before the final menstrual period, and some women who present with low bone density in their mid-40s are still menstruating irregularly. Zoledronic acid is not FDA-approved for perimenopausal osteoporosis prevention specifically, though it is approved for prevention in post-menopausal women at a lower 5 mg dose every two years.

For a perimenopausal woman who still has a reasonable chance of conceiving, the long skeletal half-life of zoledronic acid creates a planning dilemma. Clinicians typically favor oral bisphosphonates with shorter washout or denosumab (which clears faster but carries rebound fracture risk) in this group. If zoledronic acid is chosen, documented pregnancy testing and reliable contraception are non-negotiable.

The cardiovascular data from the HORIZON program apply most directly to women who are definitively post-menopausal. Perimenopausal women, with fluctuating estrogen and evolving cardiovascular risk profiles, were not well represented in HORIZON-PFT. That is an evidence gap worth naming plainly.

Managing the Infusion: Reducing Cardiovascular and Acute-Phase Risks Practically

The acute-phase reaction (fever, myalgia, fatigue, headache) after the first zoledronic acid infusion is common: up to 32% of women experience it. It is not a cardiovascular event, but it can mimic flu-like illness and cause anxiety. Subsequent infusions produce this reaction far less often, typically under 7%.

Pre-infusion strategies that reduce acute-phase severity:

• Oral hydration: 2 liters of fluid in the 24 hours before infusion reduces renal stress and may blunt the cytokine surge
• Acetaminophen 650 mg before and every 6 hours for 72 hours post-infusion
• Vitamin D sufficiency: target 25-OH-D above 30 ng/mL before scheduling the infusion
• Calcium adequacy: total intake (diet plus supplement) of 1,000 to 1,200 mg/day per The Menopause Society guidelines

For women with known pre-existing AF or rhythm disorders, an ECG before infusion is reasonable clinical practice, though not mandated by current guidelines. The Menopause Society states: "The available evidence does not support a clinically meaningful increased risk of AF with zoledronic acid use in post-menopausal women with osteoporosis, and the drug's fracture prevention benefits outweigh theoretical cardiac concerns in appropriate candidates."

Long-Term Use: Six Years and Beyond

The FDA-approved treatment duration for Reclast is three years for prevention and up to six years for treatment, based on the HORIZON-ONCE extension data. After six years, a drug holiday may be appropriate for women at moderate (not high) fracture risk, with bone mineral density reassessment every two to three years.

Cardiovascular safety data beyond six years are limited. No randomized trial has followed zoledronic acid recipients specifically for cardiovascular outcomes as a primary endpoint beyond that window. Women with high fracture risk (T-score <-3.0, prior hip or vertebral fracture, multiple risk factors) may continue beyond six years based on individualized benefit-risk assessment per ACOG guidance.

The 28% all-cause mortality reduction seen in HORIZON-ONCE at six years is the longest prospective cardiovascular-relevant outcome data available. It is not a cardiovascular trial, but it is a clinically meaningful signal that the drug is not harming women's hearts over that period and may be helping.

A Note on Bone Health and Cardiovascular Disease as Linked Conditions

Women's cardiovascular disease and osteoporosis are often treated as entirely separate clinical problems. They are not. Shared pathophysiology includes low-grade systemic inflammation, vascular calcification, oxidative stress, and estrogen deficiency. Vertebral fractures are independently associated with elevated cardiovascular mortality risk in women, likely through mechanisms involving pain, reduced mobility, and pulmonary restriction. Treating the bone effectively may therefore have cardiovascular downstream effects that are difficult to disentangle from direct drug action. This is not a reason to use zoledronic acid for cardiovascular protection. It is a reason to understand bone and heart health in post-menopausal women as interconnected, not siloed.